Trial Profile
Effectiveness and Safety of Rivaroxaban versus Warfarin in people with non‐valvular atrial fibrillation and diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2018 New trial record
- 16 Apr 2018 Results published in the Diabetic Medicine.